1973
Combined drug treatment of Hodgkin's disease: remission induction, remission duration, and survival; an appraisal.
DeVita V. Combined drug treatment of Hodgkin's disease: remission induction, remission duration, and survival; an appraisal. National Cancer Institute Monograph 1973, 36: 373-9. PMID: 4744596.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntineoplastic AgentsBiopsyCarmustineChlorambucilCyclophosphamideDactinomycinDrug Therapy, CombinationEvaluation Studies as TopicFollow-Up StudiesHodgkin DiseaseHumansMechlorethamineMiddle AgedPrednisoneProcarbazineRemission, SpontaneousTime FactorsVinblastineVincristineImmune Alterations in Hodgkin's Disease: Effect of Delayed Hypersensitivity and Lymphocyte Transformation on Course and Survival
Young R, Corder M, Berard C, DeVita V. Immune Alterations in Hodgkin's Disease: Effect of Delayed Hypersensitivity and Lymphocyte Transformation on Course and Survival. JAMA Internal Medicine 1973, 131: 446-454. DOI: 10.1001/archinte.1973.00320090136016.Peer-Reviewed Original ResearchHodgkin's diseaseLymphocyte transformationDelayed hypersensitivityFrequency of relapsesSkin test reactivityFive-year followSkin test antigensPeripheral leukocyte culturesRemission durationUntreated patientsImmune alterationsHistologic typeSkin testSystemic symptomsTest reactivityTest antigenLeukocyte culturesDiseaseHypersensitivitySurvivalDinitrochlorobenzeneCourseRelapseMumpsPatients
1972
A decade of combination chemotherapy of advanced Hodgkin's disease
Devita V, Canellos G, Moxley J. A decade of combination chemotherapy of advanced Hodgkin's disease. Cancer 1972, 30: 1495-1504. PMID: 4565815, DOI: 10.1002/1097-0142(197212)30:6<1495::aid-cncr2820300613>3.0.co;2-i.Peer-Reviewed Original ResearchConceptsAdvanced Hodgkin's diseaseComplete remission rateHodgkin's diseaseRemission rateRemission durationCombination chemotherapySingle agentLonger disease-free intervalDisease-free intervalAcute childhood leukemiaNew treatment programCombination of drugsComplete remissionComplete respondersCooperative trialsStage IIIChildhood leukemiaEffective drugsTreatment programTherapyUse of combinationsDiseasePilot studyFurther treatmentRemissionHodgkin's Disease Therapeutic Program
DeVita V. Hodgkin's Disease Therapeutic Program. JAMA 1972, 222: 1171-1171. PMID: 4678060, DOI: 10.1001/jama.1972.03210090051025.Peer-Reviewed Original ResearchConceptsCombination of drugsRemission durationHodgkin's diseaseCombinations of effective drugsProlongation of remission durationAdvanced Hodgkin's diseaseComplete remission rateAcute childhood leukemiaRemission rateProcarbazine hydrochlorideRate of inductionCooperative trialsEffective drugsChildhood leukemiaRemissionTherapyDrugPilot studyDiseaseHodgkinDurationMOPPProcarbazineMethotrexateLeukemia